US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicines

84.90

0.0000

Volume:- -

Turnover:- -

Market Cap:6.79B

PE:-27.06

High:84.90

Open:84.90

Low:84.90

Close:84.90

Loading ...

Overview Company News Filings

Revolution Medicines Is Maintained at Buy by HC Wainwright & Co.

Revolution Medicines Doses First Patient in Late-Stage Trial Evaluating Daraxonrasib to Treat Lung Cancer

MT Newswires Live

Novo Nordisk, Septerna to Collaborate on Oral Small Molecule Obesity Medicines

MT Newswires Live

Revolution Medicines Is Maintained at Buy by Guggenheim

Revolution Medicines Price Target Maintained With a $57.00/Share by Needham

Buy Recommendation for Revolution Medicines: Promising RAS(ON) Platform and Strong Financial Position

Revolution Medicines Q1 Net Loss Widens

MT Newswires Live

Revolution Medicines Q1 EPS $(1.13) Misses $(1.08) Estimate

Everest Medicines Gets China Nod for Kidney Damage Drug

MT Newswires Live

Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target

MT Newswires Live

Everest Medicines’ NEFECON® Gains Full Approval in China for IgAN Treatment

Wedbush Lifts Price Target on Praxis Precision Medicines to $28 From $26, Keeps Underperform Rating

MT Newswires Live

Praxis Precision Medicines Shares Promising EMBOLD Study Data

Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

GSK PLC (GSK) Q1 2025 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ...

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

GSK Reports Strong Q1 2025 Performance with Specialty Medicines Leading Growth

Positive Clinical Data and Competitive Efficacy Drive Buy Rating for Revolution Medicines’ Zoldonrasib

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","market":"US","secType":"STK","nameCN":"Medicines","latestPrice":84.9,"timestamp":1578085200000,"preClose":84.9,"halted":3,"volume":0,"delay":0,"floatShares":74862655,"shares":79948329,"eps":-3.137449,"marketStatus":"Halted","change":0,"latestTime":"01-03 16:00:00 EST","open":84.9,"high":84.9,"low":84.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.137449,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":965707200000,"exchange":"NASDAQ","adjPreClose":84.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","floatShares":74862655,"roa":"-13.71%","roe":"553.30%","lyrEps":-1.673974,"shares":79948329,"dividePrice":0,"high":84.9,"amplitude":0,"preClose":84.9,"low":84.9,"week52Low":23.15,"pbRate":"178.02","week52High":84.98,"institutionHeld":1.2829,"latestPrice":84.9,"eps":-3.137449,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.137449,"open":84.9,"prevYearClose":84.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535005018","title":"Revolution Medicines Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2535005018","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535005018?lang=en_us&edition=fundamental","pubTime":"2025-05-15 01:51","pubTimestamp":1747245060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2025 13:51 ET (17:51 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","RVMD"],"gpt_icon":0},{"id":"2535240570","title":"Revolution Medicines Doses First Patient in Late-Stage Trial Evaluating Daraxonrasib to Treat Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2535240570","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535240570?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:08","pubTimestamp":1747228128,"startTime":"0","endTime":"0","summary":"Revolution Medicines  said Wednesday the first patient has been dosed in a phase 3 trial evaluating daraxonrasib in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer compared to docetaxel chemotherapy.The trial is expected to enroll around 420 patients, with dual primary endpoints of progression-free survival and overall survival, the company said.The decision to evaluate daraxonrasib as a monotherapy was informed by early evidence from a single-arm trial showing that the compound had an acceptable safety profile and encouraging antitumor activity, the company said.Revolution Medicines' shares rose by more than 2% in premarket trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","BK4139","MDCO","RVMD"],"gpt_icon":0},{"id":"2535028025","title":"Novo Nordisk, Septerna to Collaborate on Oral Small Molecule Obesity Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2535028025","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535028025?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:39","pubTimestamp":1747222788,"startTime":"0","endTime":"0","summary":"Novo Nordisk  and Septerna  said Wednesday they will collaborate on a project to develop and commercialize oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases.Under the terms of the agreement, Septerna is eligible to receive about $2.2 billion from Novo Nordisk for upfront payments and research, development and commercial milestone payments, the companies said.Septerna shares jumped 63% in premarket trading, while Novo Nordisk was 2.2% higher.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"30e0cbc36438ac0be975e41ae2b7cc35","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","LU1093756168.USD","BK4532","BK7104","LU1093756325.SGD","BK4588","BK4585","IE00BKVL7J92.USD","NVO.AU","LU0154236417.USD","NVO","IE00BZ1G4Q59.USD","SEPN","BK4599","BK4007"],"gpt_icon":1},{"id":"2533341841","title":"Revolution Medicines Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2533341841","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533341841?lang=en_us&edition=fundamental","pubTime":"2025-05-08 22:31","pubTimestamp":1746714660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2025 10:31 ET (14:31 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","MDCO"],"gpt_icon":0},{"id":"2533182589","title":"Revolution Medicines Price Target Maintained With a $57.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2533182589","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533182589?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:12","pubTimestamp":1746706320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2025 08:12 ET (12:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","RVMD"],"gpt_icon":0},{"id":"2533905697","title":"Buy Recommendation for Revolution Medicines: Promising RAS(ON) Platform and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2533905697","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533905697?lang=en_us&edition=fundamental","pubTime":"2025-05-08 17:56","pubTimestamp":1746698214,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Alec Stranahan ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-recommendation-for-revolution-medicines-promising-rason-platform-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-recommendation-for-revolution-medicines-promising-rason-platform-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0348723411.USD","LU2298322129.HKD","BK4512","LU1861214812.USD","LU1548497426.USD","IE00BZ199S13.USD","LU1854103824.USD","LU2357305700.SGD","ON","LU1978683503.SGD","BK4141","LU1854104046.USD","BK4605","MDCO","LU2360107325.USD","RVMD","BK4585","LU1720051108.HKD","BK4139","LU1861219969.SGD","LU0724618433.USD","LU1720051017.SGD","LU1861220033.SGD","LU0124384867.USD","LU1861215975.USD","BK4588","IE00BD6J9T35.USD"],"gpt_icon":0},{"id":"2533967305","title":"Revolution Medicines Q1 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2533967305","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533967305?lang=en_us&edition=fundamental","pubTime":"2025-05-08 05:03","pubTimestamp":1746651795,"startTime":"0","endTime":"0","summary":"Revolution Medicines  reported a Q1 net loss late Wednesday of $1.13 per diluted share, widening from a loss of $0.70 a year earlier.Analysts polled by FactSet expected a loss of $1.12.The company did not report any revenue for the quarter ended March 31.The company expects its current cash, cash equivalents and marketable securities of $2.1 billion to fund operations into the second half of 2027.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","RVMD","BK4139"],"gpt_icon":0},{"id":"2533965046","title":"Revolution Medicines Q1 EPS $(1.13) Misses $(1.08) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533965046","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533965046?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:02","pubTimestamp":1746648166,"startTime":"0","endTime":"0","summary":"Revolution Medicines Q1 EPS $(1.13) Misses $(1.08) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45265544/revolution-medicines-q1-eps-1-13-misses-1-08-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","MDCO"],"gpt_icon":0},{"id":"2533767987","title":"Everest Medicines Gets China Nod for Kidney Damage Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2533767987","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533767987?lang=en_us&edition=fundamental","pubTime":"2025-05-07 20:34","pubTimestamp":1746621282,"startTime":"0","endTime":"0","summary":"China's medical products administrator granted full approval to Everest Medicines'  delayed-release corticosteroid budesonide for primary immunoglobulin A nephropathy, according to a Wednesday filing with the Hong Kong bourse.The drug, branded Nefecon, is indicated for adults at risk for kidney malfunction progression regardless of proteinuria or protein content in urine, the filing said.Nefecon showed a reduction in urine protein-creatinine ratio, while kidney function decline slowed by 66% among Chinese phase 3 trial participants, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","MDCO","01952","BK1161","BK1583"],"gpt_icon":0},{"id":"2533607235","title":"Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2533607235","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533607235?lang=en_us&edition=fundamental","pubTime":"2025-05-07 18:30","pubTimestamp":1746613847,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $99.27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRAX","MDCO"],"gpt_icon":0},{"id":"2533691015","title":"Everest Medicines’ NEFECON® Gains Full Approval in China for IgAN Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2533691015","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533691015?lang=en_us&edition=fundamental","pubTime":"2025-05-07 07:10","pubTimestamp":1746573026,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. ( ($HK:1952) ) has shared an announcement. Everest Medicines Ltd. announced that its drug NEFECON® has received full approva...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-nefecon-gains-full-approval-in-china-for-igan-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-nefecon-gains-full-approval-in-china-for-igan-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2533581224","title":"Wedbush Lifts Price Target on Praxis Precision Medicines to $28 From $26, Keeps Underperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2533581224","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533581224?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:55","pubTimestamp":1746449728,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $99.27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRAX","MDCO"],"gpt_icon":0},{"id":"2532703938","title":"Praxis Precision Medicines Shares Promising EMBOLD Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2532703938","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532703938?lang=en_us&edition=fundamental","pubTime":"2025-05-03 05:28","pubTimestamp":1746221312,"startTime":"0","endTime":"0","summary":"An update from Praxis Precision Medicines ( ($PRAX) ) is now available. On May 2, 2025, Praxis Precision Medicines updated its corporate presentati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/praxis-precision-medicines-shares-promising-embold-study-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/praxis-precision-medicines-shares-promising-embold-study-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCO","PRAX"],"gpt_icon":0},{"id":"2532881845","title":"Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532881845","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532881845?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:30","pubTimestamp":1746189000,"startTime":"0","endTime":"0","summary":"On track for six major study readouts across four programs over the next 12 months. Ready to initiate pivotal studies in two developmental and epileptic encephalopathy  programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen. Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability. Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its DEE portfolio [registration link]. Cash and investments of $472 million as of March 31, 2025, maintains runway into 2028. BOSTON, May 02, 2025  -- Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system  disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4561","BK4099","BK4590","ET","BK4200","ASO","TM","BK4139","BK4588","BK4555","BK4585","PRAX","03160","BK4144","AAN","MDCO","BK4178","BK4604","BK4581","BK4135"],"gpt_icon":0},{"id":"2532013290","title":"GSK PLC (GSK) Q1 2025 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2532013290","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532013290?lang=en_us&edition=fundamental","pubTime":"2025-05-01 23:01","pubTimestamp":1746111660,"startTime":"0","endTime":"0","summary":"Core Earnings Per Share: Rose 5% to GBP 0.449.Cash Generated from Operations: Over GBP 1 billion.Sales in Q1: GBP 7.5 billion, up 4% year-over-year.Vaccine Sales for Q1: Over GBP 2 billion, down 6%.General Medicine Sales: Stable, with respiratory sales up 1%.Cash Generated from Operations : GBP 1.4 billion.Free Cash Flow : Improved by GBP 0.5 billion.Royalty Income for 2025: Expected to be GBP 750 to 800 million.GuruFocus has detected 2 Warning Sign with GSK.Specialty medicines, the largest business segment, grew by 17%, driven by strong performances in respiratory, immunology, inflammation, oncology, and HIV.GSK PLC  generated over GBP1 billion in cash from operations, supporting further investment in growth and shareholder returns.Also, how might tariffs impact GSK, and what are the mitigating strategies?A:  We are excited about the new launches. For Newuara COPD, the May 7th PDUFA is on track, and we expect strong physician interest. However, pulmonologists are generally conservativ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gsk-plc-gsk-q1-2025-150100041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GSK","MDCO"],"gpt_icon":0},{"id":"2532091802","title":"Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532091802","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532091802?lang=en_us&edition=fundamental","pubTime":"2025-05-01 04:05","pubTimestamp":1746043500,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., April 30, 2025  -- Revolution Medicines, Inc. , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day , members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.About Revolution Medicines, Inc.Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS inhibitors daraxonrasib , a RAS multi-selective inhibitor; elironrasib , a RAS G12C-selective inhibitor; and zoldonrasib , a RAS G12D-selective inhibitor, are currently in clinical develop","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revolution-medicines-report-financial-results-200500076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1978683503.SGD","ON","MDCO","LU2357305700.SGD","LU1720051017.SGD","IE00BZ199S13.USD","LU1548497426.USD","RVMD","BK4141","LU0348723411.USD","LU1854104046.USD","BK4512","BK4585","LU1720051108.HKD","LU0124384867.USD","BK4605","BK4588","BK4139","LU0724618433.USD","LU2298322129.HKD","LU2360107325.USD","IE00BD6J9T35.USD","LU1854103824.USD","RVMDW","LU1861220033.SGD","LU1861215975.USD","LU1861214812.USD","LU1861219969.SGD"],"gpt_icon":0},{"id":"2531999770","title":"GSK Reports Strong Q1 2025 Performance with Specialty Medicines Leading Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2531999770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531999770?lang=en_us&edition=fundamental","pubTime":"2025-04-30 15:01","pubTimestamp":1745996479,"startTime":"0","endTime":"0","summary":"An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK reported a strong start to 2025 with significant growth in sales, profits, and e...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-reports-strong-q1-2025-performance-with-specialty-medicines-leading-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-reports-strong-q1-2025-performance-with-specialty-medicines-leading-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK","BK4007","BK4532","GSK.UK","BK4585","LU1829250122.USD","MDCO","BK4588"],"gpt_icon":0},{"id":"2531291132","title":"Positive Clinical Data and Competitive Efficacy Drive Buy Rating for Revolution Medicines’ Zoldonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2531291132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531291132?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:26","pubTimestamp":1745908003,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on RVMD stock, giving a Buy rating yesterday. Jonathan Chang has given ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-clinical-data-and-competitive-efficacy-drive-buy-rating-for-revolution-medicines-zoldonrasib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-clinical-data-and-competitive-efficacy-drive-buy-rating-for-revolution-medicines-zoldonrasib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","MDCO"],"gpt_icon":0},{"id":"2530069233","title":"Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2530069233","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530069233?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:02","pubTimestamp":1745852567,"startTime":"0","endTime":"0","summary":"\"These data reinforce the clinical potential of zoldonrasib following the initial tolerability and antitumor activity reported late last year in patients with pancreatic ductal adenocarcinoma,\" said Mark A. Goldsmith, CEO and chairman of Revolution Medicines. \"Together these results support further evaluation of zoldonrasib as monotherapy and in combination as we continue efforts to advance innovative targeted medicines for patients living with these hard-to-treat cancers,\" Goldsmith commented.RMC-9805-001 is a multicenter, open-label, dose-escalation and dose-expansion Phase 1 study designed to evaluate zoldonrasib in patients with advanced solid tumors harboring a KRAS G12D mutation.As of December 2, 2024, the data cutoff date, 90 solid tumor patients were treated with 1200 mg once daily , the candidate's recommended Phase 2 dose.In these patients, zoldonrasib demonstrated an acceptable safety profile that was generally consistent with previously reported data for this compound in pa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-cancer-drug-developer-revolution-150247153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4141","LU2357305700.SGD","LU1720051017.SGD","BK4139","LU1861215975.USD","BK4585","QD","LU2360107325.USD","IE00BZ199S13.USD","LU1978683503.SGD","LU0724618433.USD","LU1720051108.HKD","LU1548497426.USD","IE00BD6J9T35.USD","LU1854103824.USD","LU1861219969.SGD","LU0124384867.USD","BK4166","MDCO","LU2298322129.HKD","RVMDW","BK4563","BK4512","LU1854104046.USD","BK4503","ON","RVMD","LU1861220033.SGD","BK4588","BK4605","LU1861214812.USD","LU0348723411.USD"],"gpt_icon":0},{"id":"2530400545","title":"Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2530400545","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530400545?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:59","pubTimestamp":1745845141,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  said Monday its RNAi therapeutic vutrisiran, aimed at treating wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy, has received a positive opinion recommending approval from the Committee for Medicinal Products for Human Use of the European Medicines Agency.The opinion was based on phase 3 test results that showed the benefits of the drug on outcomes of mortality and cardiovascular events, as well as functional capacity, health status, and quality of life, on patients with the disease, the company said.Alnylam said it plans to proceed with additional global regulatory submissions for Vutrisiran, which received approvals from the US Food and Drug administration and the Brazilian Health Regulatory Agency this year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","MDCO","BK4139","ALNY","BK4548","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":153,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCO\",params:#limit:5,,,undefined,":[{"date":"2019-10-30","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"defaultRemindTime":1572422400000,"name":null,"time":"Pre-Market","dateTimestamp":1572408000000,"actualEps":null},{"date":"2019-07-24","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.66,"defaultRemindTime":1563955200000,"name":null,"time":"Pre-Market","dateTimestamp":1563940800000,"actualEps":-0.67},{"market":"US","date":"2019-04-25","symbol":"MDCO","fiscalQuarterEnding":"2019/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1556164800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2019-02-27","symbol":"MDCO","fiscalQuarterEnding":"2018/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2018-11-08","symbol":"MDCO","fiscalQuarterEnding":"2018/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCO\",market:\"US\",delay:false,,,undefined,":{}}}